You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
成大生物(688739.SH):合作研發的13價肺炎球菌結合疫苗正式進入I期臨牀試驗
格隆匯 11-08 16:42

格隆匯11月8日丨成大生物(688739.SH)公佈,近日,公司與武漢博沃生物科技有限公司合作研發的13價肺炎球菌結合疫苗,已完成I期臨牀試驗準備工作,正式進入I期臨牀試驗。疫苗產品的研發週期長、審批環節多,容易受到一些不確定性因素的影響,敬請廣大投資者謹慎決策,注意防範投資風險。

13價肺炎球菌結合疫苗主要用於嬰幼兒和兒童,接種後可使機體產生免疫應答,可以預防由肺炎球菌引起的侵襲性疾病(包括菌血症性肺炎、腦膜炎、敗血症和菌血症)。13價肺炎球菌結合疫苗是世界上最暢銷的疫苗品種之一,2020年在全球銷售額約61億美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account